Liquidia Corp (LQDA): Price-to-Revenue Ratio

Brandmark of Liquidia Corp (LQDA)

The use of the PRINT system for the precise synthesis of drug microparticles drives the P/S ratio chronology on the GURU.Markets chart, where 8.30 serves as the final level marker for Liquidia Corporation (LQDA). Demand for orphan drugs makes the business resilient to economic downturns; however, protracted patent litigation and regulatory barriers exert significant pressure on the pace of commercialization.

Liquidia Corporation (LQDA): Price-to-Revenue Ratio from 07/04/2022 to 11/15/2026

Analytical breakdowns for liquidia.com (LQDA)

- share price and consensus valuation forecast:
Price Performance Chart Liquidia Corp|LQDA - Price Target Chart
- stock exchange capitalization data:
Market Value Liquidia Inc.|LQDA - Enterprise Value
- issuer book value statistics:
Net Assets per Share Liquidia|LQDA - Company Book Value|Market Value to Equity Ratio liquidia.com|LQDA - Cumulative Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Liquidia Corporation|LQDA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Liquidia Corporation|LQDA - Company Aggregate Debts|Debt to Book Value Ratio Liquidia Inc.|LQDA - Company Long-Term Debts|Short-Term Debt Volume Liquidia|Quick Ratio liquidia.com
- net income and valuation ratios data:
LQDA - Net Income|Expected Net Income Liquidia Corporation|LQDA - P/E Multiple|Projected Price to Earnings Liquidia Inc.|LQDA - Price/Earnings to Growth Ratio|Company Value to EBITDA Liquidia|LQDA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Liquidia|LQDA - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months liquidia.com|LQDA - Earnings per share growth in current year|Expected net earnings per share growth next year Liquidia Corporation
- total revenue and sales volume data:
LQDA - Company Revenue|Company Future Revenue Liquidia|LQDA - P/S Multiple|Forward P/S Multiple Liquidia Corporation
General company analysis:Liquidia (LQDA)
Signature product of Liquidia Corporation

The P/S ratio determines the market value of one unit of annual turnover, allowing for an assessment of the premium paid for a business relative to its ability to generate revenue. By analyzing the P/S of Liquidia Corporation (LQDA), an investor can gauge market expectations for the commercialization of its inhalation systems, where the indicator's trend reflects market confidence in the success of its proprietary drugs for pulmonary hypertension therapy.

Competing companies

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Galapagos Corp|Price-to-Revenue Ratio ANI Pharma (ANIP)|P/S Multiple MannKind Corporation (MNKD)|Price-to-Revenue Ratio Amphastar Pharmaceuticals Inc AMPH|P/S Multiple Pacira PCRX|ARS Pharmaceuticals Inc - P/S Multiple|TBPH - P/S Multiple|AQST (Aquestive Therapeutics) - Market Cap to Revenue|scPharmaceuticals, Inc. (SCPH) - P/S Multiple|Market Cap to Revenue TECX|P/S Multiple Tonix Pharma|Market Cap to Revenue SXTC (SXT Pharmaceuticals)|EPRX: Price-to-Sales Ratio|BioHarvest Sciences - Market Cap to Revenue|EXOZ: Market Cap to Revenue Ratio|ORMP - Price-to-Revenue Ratio|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)